Sandu Pharmaceuticals Limited (BOM:524703)

Sandu Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	-	68.56	26.53	12.06	22.76	9.39
Short-Term Investments	-	-	-	-	0.2	32.33
Cash & Short-Term Investments	68.56	68.56	26.53	12.06	22.96	41.71
Cash Growth	158.42%	158.42%	119.93%	-47.45%	-44.96%	-64.21%
Accounts Receivable	-	54.11	47.57	48.68	47.92	39.91
Other Receivables	-	0.72	0.32	0.62	3.17	4.28
Receivables	-	55.14	49.12	50.32	52.13	45.09
Inventory	-	104.72	141.49	122.51	143.26	112.72
Prepaid Expenses	-	2.87	1.86	1.15	0.76	0.87
Other Current Assets	-	21.92	43.99	37	36.35	36.08
Total Current Assets	-	253.2	262.99	223.04	255.45	236.47
Property, Plant & Equipment	-	181.06	181.22	178.43	169.86	164.5
Long-Term Investments	-	123.29	112.74	122.33	115.61	91.39
Other Intangible Assets	-	0.83	0.24	0.35	0.51	0.35
Other Long-Term Assets	-	0.32	-	0	0.24	0.14
Total Assets	-	558.69	557.19	524.15	541.66	492.85

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	-	44.68	44.88	41.95	83.98	68.18
Accrued Expenses	-	31.31	30.36	32.98	29.07	25.65
Current Portion of Leases	-	1.1	0.58	0.03	-	-
Current Income Taxes Payable	-	6.66	25	19.12	13.25	15.28
Current Unearned Revenue	-	10.4	6.69	5.15	7.3	6.06
Other Current Liabilities	-	10.08	13.36	7.19	5.24	3.57
Total Current Liabilities	-	104.22	120.86	106.41	138.83	118.74
Long-Term Leases	-	3.1	4.19	0.6	-	-
Long-Term Deferred Tax Liabilities	-	14.64	11.96	11.21	10.42	9.37
Other Long-Term Liabilities	-	-0	-	-	-	-
Total Liabilities	-	121.96	137.02	118.22	149.25	128.1

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	-	96.61	96.61	96.61	96.61	88.11
Additional Paid-In Capital	-	27.58	27.58	27.58	27.58	18.49
Retained Earnings	-	201.67	190.27	180.88	171.95	161.8
Comprehensive Income & Other	-	110.88	105.71	100.86	96.27	96.35
Shareholders' Equity	436.73	436.73	420.17	405.93	392.41	364.75
Total Liabilities & Equity	-	558.69	557.19	524.15	541.66	492.85

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	4.19	4.19	4.78	0.63	-	-
Net Cash (Debt)	64.37	64.37	21.76	11.43	22.96	41.71
Net Cash Growth	195.87%	195.87%	90.33%	-50.21%	-44.96%	-64.16%
Net Cash Per Share	7.34	6.66	2.25	1.18	2.43	4.91
Filing Date Shares Outstanding	6.17	9.66	9.66	9.66	9.66	8.81
Total Common Shares Outstanding	6.17	9.66	9.66	9.66	9.66	8.81
Working Capital	-	148.97	142.13	116.63	116.62	117.74
Book Value Per Share	40.25	45.21	43.49	42.02	40.62	41.40
Tangible Book Value	436.55	435.91	419.93	405.58	391.91	364.4
Tangible Book Value Per Share	40.23	45.12	43.47	41.98	40.57	41.36
Buildings	-	86.58	86.26	86.16	85.84	81.31
Machinery	-	108.99	102.56	97.61	81.87	75.42
Construction In Progress	-	-	-	-	4.2	4.82

Data Source: S&P Global Market Intelligence Last updated: Aug 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 7, 2026

Data Sources Report a data error